Navigation Links
Baxter and Halozyme Announce Collaboration for Development of Subcutaneous GAMMAGARD LIQUID(TM) Administration Using Enhanze(TM) Technology
Date:9/10/2007

Development of New Route to Administer GAMMAGARD LIQUID(TM) 10% Could Make Home Therapy More Accessible; Collaboration Valued at Up to $47 Million

DEERFIELD, Ill. and SAN DIEGO, Sept. 10 /PRNewswire-FirstCall/ -- Baxter International Inc. (NYSE: BAX) and Halozyme Therapeutics, Inc. (Nasdaq: HALO) announced today they have entered into an agreement to apply Halozyme's proprietary Enhanze(TM) Technology to the development of a subcutaneous route of administration for Baxter's GAMMAGARD LIQUID(TM) 10% [Immune Globulin Intravenous (Human)] (IGIV) (known as KIOVIG(TM) in Europe). For patients using GAMMAGARD LIQUID 10% -- currently administered intravenously -- subcutaneous administration with Enhanze Technology may increase overall convenience and improve the dispersion of the therapy.

Under the terms of the agreement, Baxter will provide Halozyme an initial upfront payment of $10 million. Pending successful completion of a series of regulatory and sales milestones, Baxter may make further milestone payments totaling $37 million to Halozyme. Baxter also will assume development, manufacturing, clinical, regulatory, sales and marketing costs. Halozyme will be responsible for the supply of the recombinant human hyaluronidase (rHuPH20) enzyme that provides the basis for Enhanze Technology. Upon regulatory approval, Halozyme will also receive royalties on GAMMAGARD LIQUID 10% administered subcutaneously using Enhanze Technology both in kits and in co- formulations.

Bax
'/>"/>

SOURCE Baxter International Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Speaker announces business members of IT Task Force
2. Doyle announces technology tax credits for Berbee
3. Doyle announces new energy, global warming policies
4. Doyle, WARF announce partnership to lure stem cell companies
5. Doyle announces $80M renewable energy strategy
6. GE announces first installation of Discovery VCT
7. UWM announces winners of RGI awards
8. Third Wave announces two senior management appointments
9. Mirus announces new method for making antibodies
10. Merge announces sofware updates, upcoming acquisition
11. Small Tree announces ethernet solution for Apple Xserv G5
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... PuraMed BioScience ® , Inc., (OTCBB: ... (OTC) medicinal and healthcare products, announced that Ludlow ... based on low market capitalization valuation. ... Product to Treat Migraine Headaches , Clinical ... , Currently Available Nationwide at Walgreen,s and ...
(Date:5/23/2013)... , May 23, 2013  Saddleback Memorial Medical ... recently became the first hospital on the West Coast ... This new surgical option provides women with a state-of-the-art, ... Marc Winter , M.D., a highly ... surgeon and medical director of minimally invasive surgery at ...
(Date:5/23/2013)... Md. , May 23, 2013 Northwest ... biotechnology company developing DCVax ® personalized immune therapies ... use its exhibit at this year,s American Society Of ... to highlight its leadership role in immune therapy.  ... The ASCO annual meeting is the pre-eminent conference focused ...
(Date:5/23/2013)... , May 23, 2013 Pusan ... Inc., a private biotherapeutics and contract research company ... products for cancer, announced today a publication reporting ... treated with the oncolytic and immunotherapeutic vaccinia JX-594 ... research was published in the May 15 th ...
Breaking Biology Technology:PuraMed BioScience (PMBS) Issued Alert Based on Market Cap of $721,756 2PuraMed BioScience (PMBS) Issued Alert Based on Market Cap of $721,756 3Saddleback Memorial Surgeon First on the West Coast to Perform Single-Site Robotic Hysterectomy 2Saddleback Memorial Surgeon First on the West Coast to Perform Single-Site Robotic Hysterectomy 3NW Bio Exhibit at the Upcoming ASCO Meeting to Highlight its Leadership Role in Immune Therapy for Cancer 2NW Bio Exhibit at the Upcoming ASCO Meeting to Highlight its Leadership Role in Immune Therapy for Cancer 3Pusan National University Announces Science Translational Medicine Publication Highlighting Landmark Demonstration of Functional Anti-Cancer Antibody Induction in Patients Following JX-594 Treatment 2Pusan National University Announces Science Translational Medicine Publication Highlighting Landmark Demonstration of Functional Anti-Cancer Antibody Induction in Patients Following JX-594 Treatment 3
... Inc. (TSX: ONC, NASDAQ: ONCY ) ("Oncolytics") ... U.S. Patent, # 7,582,289, entitled "Viruses for the Treatment ... of using modified parapoxvirus orf virus to treat Ras-mediated ... portfolio regarding oncolytic viruses, in addition to reovirus, that ...
... WILMINGTON, Delaware, September 1 According ... (2009-2014),published by MarketsandMarkets ( http://www.marketsandmarkets.com ), the,global autoimmune ... 2014, with an estimated CAGR of 12.7% from 2009 ... for nearly 42% of the total revenues. , ...
... ... of continuous research, experiments and trials have given Centre for Jatropha Promotion ... alternative feedstock for biodiesel. After having a number of successful field trials ... source for Bio- Diesel industry of future and is happy to announce ...
Cached Biology Technology:Oncolytics Biotech(R) Inc. Announces Issuance of 32nd U.S. Patent 2MarketsandMarkets: Global Autoimmune Treatment Market Worth US$68.81 Billion by 2014 2MarketsandMarkets: Global Autoimmune Treatment Market Worth US$68.81 Billion by 2014 3MarketsandMarkets: Global Autoimmune Treatment Market Worth US$68.81 Billion by 2014 4Derris Indica is CJP's New Nonfood Biodiesel Crop for Profitable Sustainability 2Derris Indica is CJP's New Nonfood Biodiesel Crop for Profitable Sustainability 3
(Date:5/23/2013)... be the world,s most popular fruit, can be made ... purple GM varieties. , "Working with GM tomatoes ... addition of a specific compound, allows us to pinpoint ... Cathie Martin from the John Innes Centre. , The ... flavour, health and shelf life characteristics because even higher ...
(Date:5/23/2013)... discovering the new mechanism by which estrogen suppresses lipid ... a potential new approach toward treating certain liver diseases. ... colleagues believe they are changing long-held views in the ... of the journal Science Signaling . , "The ... has been that only receptors located in the nucleus ...
(Date:5/23/2013)... 23, 2013) A new report from the Institute ... pupils engage in at least 60 minutes of vigorous ... No more than half of American youth meet current ... or moderate intensity physical activity daily, according to the ... are in school for nearly half of their waking ...
Breaking Biology News(10 mins):The world's favorite fruit only better-tasting and longer-lasting 2UCI study reveals new mechanism for estrogen suppression of liver lipid synthesis 2Schools should provide students with daily physical activity, IOM recommends 2
... of obesity among South Asians to be recalculated has been ... A team from the University,s Departments of Health Sciences and ... which South Asians should be classed as obese to be ... One , a journal of the Public Library of Science. ...
... three-person start-up may well be on its way to ... team of young Dutch scientists pushing disruptive biotech innovations ... attention of some key investors and demonstrating the added ... with the Eurostars funding programme leading the way. ...
... Spanish . CHICAGO -- A 10-year ... infants with high hemoglobin levels who received iron fortified infant ... in Santiago, Chile, was published online today ahead of print ... and raises questions about the optimal amount of iron in ...
Cached Biology News:New research calls for lower limit to be set for South Asian obesity level 2Biotech start-up brings DNA-sequencing to the medical market 2Biotech start-up brings DNA-sequencing to the medical market 3Routine iron fortification of infant formula linked to poorer development 2Routine iron fortification of infant formula linked to poorer development 3
Mouse monoclonal antibody raised against a partial recombinant CALCOCO2. NCBI Entrez Gene ID = CALCOCO2...
Mouse polyclonal antibody raised against a partial recombinant KCTD13. NCBI Entrez Gene ID = 253980...
... pLivSelect is a direct antibiotic-based selection system ... on colony survival, eliminating the need for ... process provides close to 100% accuracy in ... platform for robot colony picking. This ...
Alpha-2-antiplasmin precursor (Alpha-2-plasmin inhibitor) (Alpha-2-PI) (Alpha-2-AP). [Source:Uniprot/SWISSPROT;Acc:P08697] Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
Biology Products: